Dr. William Wierda on Ibrutinib and Idelalisib as Treatments in NSCLC
William G. Wierda, MD, PhD, discusses ibrutinib and idelalisib as treatments for non-small cell lung cancer. Wierda says that as it currenlty stands, ibrutinib is approved only for patients with NSCLC with a 17p deletion untreated and idelalisib is only approved for patients with untreated NSCLC.
William G. Wierda, MD, PhD, professor of medicine, MD Anderson Cancer Center, discusses ibrutinib and idelalisib as treatments for non-small cell lung cancer. Wierda says that as it currenlty stands, ibrutinib is approved only for patients with NSCLC with a 17p deletion untreated and idelalisib is only approved for patients with untreated NSCLC.
He adds that while both treatments are effective, he hopes in the future they can be used less in order to give patients downtime between treatments. Wierda says most patients respond to the treatments, though their responses are only a partial remission. He adds that patients usually experience a period of progression-free survival for both drugs in the salvage setting, both as monotherapies and idelalisib in combination with rituxumab.
Zipalertinib Shows Promise in Heavily Pretreated EGFR Exon 20-Mutated NSCLC
September 14th 2024Zipalertinib appeared safe and effective in the treatment of heavily pretreated patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed on or after amivantamab.
Read More
